QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
NASDAQ:ATRC

AtriCure - ATRC Stock Forecast, Price & News

$52.61
-0.01 (-0.02%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$50.99
$52.96
50-Day Range
$35.10
$52.62
52-Week Range
$32.83
$89.18
Volume
222,333 shs
Average Volume
264,790 shs
Market Capitalization
$2.44 billion
P/E Ratio
45.35
Dividend Yield
N/A
Price Target
$75.86

AtriCure MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
44.2% Upside
$75.86 Price Target
Short Interest
Healthy
3.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of AtriCure in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.09) to ($0.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

190th out of 1,124 stocks

Surgical & Medical Instruments Industry

16th out of 113 stocks

ATRC stock logo

About AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ATRC. StockNews.com upgraded AtriCure from a "sell" rating to a "hold" rating in a report on Monday. BTIG Research decreased their price objective on AtriCure from $94.00 to $75.00 and set a "buy" rating for the company in a report on Friday, June 24th. Stifel Nicolaus decreased their price objective on AtriCure from $70.00 to $50.00 in a report on Monday, July 18th. Piper Sandler decreased their price objective on AtriCure from $90.00 to $55.00 and set an "overweight" rating for the company in a report on Wednesday, August 3rd. Finally, Needham & Company LLC lifted their price objective on AtriCure from $55.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday, August 3rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $75.86.

AtriCure Price Performance

ATRC opened at $52.62 on Tuesday. The business's 50-day moving average is $43.66 and its two-hundred day moving average is $52.66. AtriCure has a 1 year low of $32.83 and a 1 year high of $89.18. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.66 and a quick ratio of 2.93. The firm has a market capitalization of $2.44 billion, a PE ratio of 45.36 and a beta of 1.20.

AtriCure (NASDAQ:ATRC - Get Rating) last posted its earnings results on Tuesday, August 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). AtriCure had a net margin of 17.62% and a negative return on equity of 11.47%. During the same period in the previous year, the business posted ($0.30) earnings per share. Research analysts anticipate that AtriCure will post -1.09 earnings per share for the current fiscal year.

Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

ATRC Stock News Headlines

AtriCure (NASDAQ:ATRC) Cut to "Sell" at StockNews.com
AtriCure (NASDAQ:ATRC) Lowered to Sell at StockNews.com
AtriCure (NASDAQ:ATRC) PT Lowered to $55.00 at Piper Sandler
AtriCure (NASDAQ:ATRC) PT Raised to $65.00
Is AtriCure (NASDAQ:ATRC) Using Too Much Debt?
AtriCure (ATRC) Set to Announce Quarterly Earnings on Tuesday
AtriCure (NASDAQ:ATRC) Cut to Sell at StockNews.com
See More Headlines
Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

ATRC Company Calendar

Last Earnings
8/02/2022
Today
8/16/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ATRC
CUSIP
04963C20
Employees
875
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$75.86
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+44.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$50.20 million
Pretax Margin
17.68%

Debt

Sales & Book Value

Annual Sales
$274.33 million
Cash Flow
$0.96 per share
Book Value
$10.53 per share

Miscellaneous

Free Float
45,125,000
Market Cap
$2.44 billion
Optionable
Optionable
Beta
1.20

Social Links















ATRC Stock - Frequently Asked Questions

Should I buy or sell AtriCure stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings
or view top-rated stocks.

What is AtriCure's stock price forecast for 2022?

5 Wall Street research analysts have issued 1-year price objectives for AtriCure's stock. Their ATRC share price forecasts range from $50.00 to $110.00. On average, they expect the company's stock price to reach $75.86 in the next twelve months. This suggests a possible upside of 44.2% from the stock's current price.
View analysts price targets for ATRC
or view top-rated stocks among Wall Street analysts.

How have ATRC shares performed in 2022?

AtriCure's stock was trading at $69.53 at the beginning of the year. Since then, ATRC shares have decreased by 24.3% and is now trading at $52.61.
View the best growth stocks for 2022 here
.

When is AtriCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ATRC earnings forecast
.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) released its quarterly earnings data on Tuesday, August, 2nd. The medical device company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.02. AtriCure had a negative trailing twelve-month return on equity of 11.47% and a net margin of 17.62%. During the same quarter last year, the company posted ($0.30) earnings per share.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of -$1.12--$1.07 for the period, compared to the consensus EPS estimate of -$1.10. The company issued revenue guidance of $323.00 million-$333.00 million, compared to the consensus revenue estimate of $324.43 million.

What is Michael Carrel's approval rating as AtriCure's CEO?

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

What other stocks do shareholders of AtriCure own?
What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (3.88%), First Light Asset Management LLC (3.19%), Macquarie Group Ltd. (2.92%), Credit Suisse AG (2.41%), State Street Corp (2.26%) and Loomis Sayles & Co. L P (1.99%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends
.

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $52.61.

How much money does AtriCure make?

AtriCure (NASDAQ:ATRC) has a market capitalization of $2.44 billion and generates $274.33 million in revenue each year. The medical device company earns $50.20 million in net income (profit) each year or $1.16 on an earnings per share basis.

How many employees does AtriCure have?

The company employs 875 workers across the globe.

Does AtriCure have any subsidiaries?
The following companies are subsidiares of AtriCure: SentreHEART.
Read More
When was AtriCure founded?

AtriCure was founded in 2000.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for the company is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567.

This page (NASDAQ:ATRC) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.